Brean Capital Reiterates Buy on Pitney Bowes (PBI) Following Earnings Report and Sell Off
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Notable 52-Week Highs and Lows 11/1: (AMKR) (ADM) (WCG) High; (BKD) (PBI) Low
November 1, 2016 3:51 PM EDT52-Week High:Amkor Technology (Nasdaq: AMKR) $10.80. Amkor Technology reported Q3 EPS of $0.25, versus the analyst estimate of $0.21. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.06 billion. Amkor Technology sees FY2016 EPS of $0.55, versus the consensus of $0.42. Amkor Technology sees FY2016 revenue of $3.9 billion, versus the consensus of $3.86 billion.
Unusual 11 Mid-Day Movers 11/1: (NSPR) (OCLS) (IFMI) Higher; (NVCN) (INST) (GLT) Lower
November 1, 2016 12:57 PM EDTInspireMD, Inc. (NYSE: NSPR) 137.2% HIGHER; announced 12-month follow up data from PARADIGM-101 of the CGuard Embolic Prevention System (EPS) which were presented in two presentations at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific symposium, taking place October 29 - November 2 in Washington, D.C. at the Walter E. Washington Convention Center. For more color, click here.
Neovasc... More
Pitney-Bowes (PBI) Misses Q3 EPS by 2c; Sees Being at Lower-End of Guidance
November 1, 2016 7:14 AM EDTPitney-Bowes (NYSE: PBI) reported Q3 EPS of $0.44, $0.02 worse than the analyst estimate of $0.46. Revenue for the quarter came in at $839 million versus the consensus estimate of $851.82 million.
The Company expects to be at the low-end of its annual guidance range for revenue and... More
